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148 counts/min, p  ! 0.05 in all instances). Out of 19 patients 
followed for 4 years, 5 died and 1 received a lung transplan-
tation. Kaplan-Meier analysis revealed a shorter survival 
without lung transplantation in patients with a duration of 
daytime activity of  ! 15 h/day than those with  1 15 h/day du-
ration (log rank, p = 0.026).  Conclusion: A long nocturnal rest 
and reduced daytime activity recorded by actigraphy are
associated with severe hemodynamic impairment and re-
duced survival in patients with PH. Therefore, wrist actigra-
phy performed during everyday life in the patient’s home 
holds promise as a simple tool for the assessment of disease 
severity and prognosis in patients with PH. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Pulmonary hypertension (PH) is a severe condition 
leading to progressive right heart failure with impaired 
quality of life, reduced exercise capacity and premature 
death. Two major groups of PH include pulmonary arte-
rial hypertension, which is either idiopathic or associated 
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 Abstract 
 Background: Pulmonary hypertension (PH) impairs quality 
of life, exercise performance and survival. Simple measures 
to monitor the disease are needed.  Objectives: We tested 
whether actigraphy by a wrist-worn device in the patient’s 
home reflects disease severity in PH patients.  Methods: 
Twenty-three outpatients with pulmonary arterial and 
chronic thromboembolic PH (15 females), functional classes 
II–IV, underwent clinical examination and actigraphy over 2 
weeks while pursuing their usual life at home. Actigraphies 
were correlated with clinical data and mean pulmonary ar-
tery pressure (mPAP). Deaths, lung transplantations and pul-
monary endarterectomy were recorded over 4 years.  Re-
sults: Actigraphies revealed a mean  8 SD daytime activity 
duration of 14: 57  8 1: 14 h with 146  8 125 activity counts/
min. Very severely impaired patients (mPAP 50  8 7 mm Hg) 
were inactive for longer periods at night (8: 25  8 1: 18 h) and 
less active during the day (54  8 44 counts/min) when com-
pared to modestly impaired patients (mPAP 33  8 7 mm Hg; 
inactive at night for 6: 58  8 0: 39 h; daytime activity 229  8 
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with different conditions, and chronic thromboembolic 
PH, i.e. groups 1 and 4 according to the Dana Point Clas-
sification  [1] . An increasing number of therapeutic agents 
including prostanoids, endothelin receptor antagonists 
and phosphodiesterase-5 inhibitors have been shown to 
be effective in pulmonary arterial and inoperable chron-
ic thromboembolic PH  [2–6] . Pulmonary endarterecto-
my is the treatment of choice in suitable candidates with 
chronic thromboembolic PH  [7, 8] . Despite advances in 
therapies, PH is still incurable; intense research on new 
therapeutics is therefore ongoing. PH affects many do-
mains of the daily life of an individual such as participa-
tion in social activities, work, recreation and household 
tasks. Some of these aspects can be evaluated by question-
naires and by symptom scales such as the WHO func-
tional class. However, questionnaire evaluations are con-
founded by a high inter- and intraindividual variability. 
Therefore, there is a need for objective assessment of the 
clinical course and response to treatment in PH patients. 
Repeated right-heart catheterization is not practical be-
cause of its invasive nature and Doppler echocardiogra-
phy lacks precision. Measurement of the exercise perfor-
mance by spiroergometry and the 6-min walk test 
(6MWT) can provide valuable information, but the re-
sults are susceptible to movement and skeletal muscle 
limitations. Moreover, a single test performed in a physi-
cian’s office may not represent an individual’s perfor-
mance in everyday life.
 An actigraph placed on the wrist like a watch enables 
a continuous record of movements to be kept during the 
usual everyday activities of the patients in their home 
over prolonged periods of time (from days to weeks). Ac-
tigraphy is used to measure periods of rest as surrogates 
of sleep and to quantify activity during wakefulness in a 
variety of patient groups  [9–12] . The technique is simple 
to use and unobtrusive. We reasoned that actigraphy 
might complement the self-reports and clinical assess-
ment of PH patients, thereby increasing our understand-
ing of limitation in activity and disability in PH. The
purpose of this study was to perform actigraphy in PH 
patients and to correlate the results with questionnaire 
assessments, exercise capacity, sleep studies and out-
come. Compared to patients with mild PH, patients with 
more severe hemodynamic compromise display reduced 
physical activity, and some are confined to their homes 
and have a poor prognosis  [13] . We tested the hypothesis 
that daytime activity measured by wrist actigraphy in pa-
tients with pulmonary arterial or chronic thromboem-
bolic PH is correlated with the severity of PH assessed by 
right-heart catheter and survival.
 Material and Methods 
 Patients 
 Consecutive patients with PH classified as being either pulmo-
nary arterial or chronic thromboembolic were asked to partici-
pate  [14] . PH was defined according to WHO classification and 
patients were included if PH was idiopathic or associated with col-
lagen vascular, congenital heart or chronic thromboembolic dis-
ease  [1] . Patients were in a stable condition on the same medica-
tion for  1 4 weeks. The study was approved by our ethical board 
and all patients gave their written informed consent.
 General Baseline Assessments 
 Patients were physically examined; current medication and 
functional class were noted. Questionnaire evaluation included 
quality of life [short-form (SF)-36 questionnaires]  [15, 16] and 
sleepiness by the Epworth scale  [17] . A 6MWT was performed. 
Hemodynamic data from the last right-heart catheterization were 
noted. PH was grouped according to hemodynamics in modest 
[mean pulmonary artery pressure (mPAP) = 26–39 mm Hg], se-
vere (mPAP  6 40) and very severe (mPAP  6 40 with mixed ve-
nous oxygen saturation  ! 60%)  [18] . Venous N-terminal pro-brain 
natriuretic peptide (NT-proBNP) was measured  [19, 20] . Sleep 
studies were performed as previously described  [14] .
 Actigraphy 
 Patients wore an actigraph (Actiwatch  Model AW4, Neuro-
technology Ltd., Cambridge, UK) on their nondominant wrist for 
2 weeks. They were instructed to press a marker button on the 
actigraph when they went to bed in the evening and got up in the 
morning. They recorded their bedtime, the time they got up in the 
morning and any special events in a diary. Data stored in the in-
ternal memory of the actigraph were downloaded into a comput-
er for analysis.
 The Actiwatch actigraph measures activity with a piezoelectric 
accelerometer that records amounts, duration and intensity of 
movements in all directions at a sampling rate of 32 Hz. Accelera-
tions over 0.05  g are recorded and their sum during consecutive 
epochs of 1 min is stored in the internal memory of the actigraph. 
 Actigraphic data were analyzed with commercially available 
software (sleep analysis V 7.2). The following data were obtained: 
time in bed, estimated total sleep time (time with inactivity dur-
ing time in bed), sleep efficiency (ratio of estimated total sleep 
time to time in bed) and sleep fragmentation index (number of 
short immobility phases  ^  1 min divided by the number of unin-
terrupted immobility phases lasting for  1 1 min). Daytime activ-
ity duration was defined as the time with activity between the first 
phase of activity after arising and the last phase of activity before 
bedtime. Counts per phase of activity during the day were calcu-
lated. Naps were defined as periods with inactivity during the day.
 Follow-Up 
 Patients were followed up at our clinic half-yearly during the 
first year and thereafter yearly over at least 4 years following the 
initial evaluation. Regular assessments included a clinical exami-
nation, a 6MWT and whatever other examinations were clini-
cally indicated. The dates of death and lung transplantation were 
recorded. The cause of death was determined by contacting the 
physicians involved in the care of the patients and by reviewing 
the medical records.
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 Data Analysis and Statistics 
 We compared means using the Mann-Whitney rank-sum test, 
ANOVA and the Fisher test as appropriate. Correlation analysis 
was with the Pearson correlation and linear regression. The Kap-
lan-Meier analysis of transplantation-free survival was performed 
and potential predictors of survival were evaluated by multivari-
ate Cox regression models. Statistical significance was accepted 
as p  ! 0.05. 
 Results 
 Patients 
 Table 1 shows the characteristics of the 23 study par-
ticipants. Thirteen patients suffered from pulmonary ar-
terial and 10 from chronic thromboembolic PH. Patients 
were in WHO functional classes II–IV, had a decreased 
6MWT, and an elevated proBNP. They were on stable 
therapy with bosentan  [13] , sildenafil  [13] and inhaled 
iloprost  [5] for 17  8 14 months; 9 had combination ther-
apy. In 4 eligible patients with chronic thromboembolic 
disease, pulmonary endarterectomy was performed 11  8 
12 months after actigraphy. Eleven of the 23 patients had 
an elevated apnea/hypopnea index  1 10/h mainly due to 
central events ( table 1 ). Overnight oximetry revealed that 
patients spent an average of 33% of their time in bed with 
a low oxygen saturation  ! 90%. 
 Actigraphy 
 The typical actigraphy patterns of a patient with mod-
erate PH and of a patient with severe PH are shown in 
 figure 1 .  Table 2 provides summary statistics of actigraph-
ic data. The average time in bed was 7: 32  8 1: 05 h with a 
sleep efficiency of 92  8 9% ( table 2 ). Actigraphic mea-
sures reflecting sleep disruption, i.e. sleep efficiency and 
the fragmentation index, were correlated with overnight 
oxygen saturation (r = 0.496, p = 0.019 and r = –0.530, p = 
0.011) and with subjective sleepiness assessed by the Ep-
worth sleepiness score (r = –0.438, p = 0.041 and r = 0.511, 
p = 0.015). Women had a significantly longer nap time 
than men (17.4  8 7.1 vs. 12.4  8 3.2 min, p = 0.027). Pa-
tients with chronic thromboembolic PH had significantly 
less activity counts/phases at baseline compared to pa-
tients with pulmonary arterial hypertension (186  8 136 
vs. 81  8 70, p = 0.04) although they did not differ from 
the other patients with regard to hemodynamics, 6-min 
walk distance or quality of life measures (data not shown).
 Actigraphy in Patients with Different PH Severities 
 In  table 3 , patients are grouped according to PH sever-
ity. Daytime activity expressed in total counts and counts 
per 1-min phase decreased with PH severity (p = 0.026 
and 0.019, respectively). Individual times in bed were sig-
nificantly correlated with the pulmonary vascular resis-
tance (r = 0.515, p = 0.017). Daytime activity duration and 
counts/phases were associated with increased quality of 
life (SF-36 questionnaire on general health and vitality;
r = –0.557, p = 0.006 and r = 0.507, p = 0.022).
Table 1. P atient characteristics
Number of patients; females/males 23; 15/8
Age, years 58816
Classification of PH
Idiopathic
Connective tissue disease
Chronic thromboembolic 
11 (48)
2 (9)
10 (43)
W HO functional class II/III/IV 10/8/5 
(43/35/22)
BMI 2583
Mean pulmonary arterial pressure, mm Hg 43810
Pulmonary vascular resistance, dynscm–5 7208303
Cardiac index, l/min/m2 2.380.7
NT-proBNP, ng/l (normal value <130) 1,57983,181
6-min walking distance, m 5088115
Apnea/hypopnea index total, events/h 
Obstructive
Central
12811
285
1088
Mean nocturnal oxygen saturation, % 90.183.4
Time spent with oxygen saturation <90% 
in % of time in bed 33836
SF-36 quality of life
Physical component summary score
Mental component summary score
34810
49811
Epworth sleepiness score 7.585
Values are n (%) or means 8 SD. Ep worth score ranges from 
0–24 with ≥11 points considered excessive sleepiness. SF-36 = 
Short form of the medical outcome questionnaire, presented as 
transformed scores; lower values correspond to poorer quality of 
life.
Table 2. A ctigraphy data (means 8 SD)
Actigraphy on wrist, days 1582
Time in bed, h 7:3281:05
Sleep efficiency, % 9189
Sleep fragmentation index 27813
Daytime activity duration, h 14:5781:10
Total daytime activity count, !104 12.9811.1
Average daytime activity, counts/min 1468125
Daily naps, n 3.683.6
Total nap duration, h 1:1081:13
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 Follow-Up 
 Operable patients with chronic thromboembolic PH 
underwent pulmonary endarterectomy within a few 
months after baseline and were excluded from the sur-
vival analysis because the indication for surgery is not ex-
clusively determined by disease severity. During the 
4-year follow-up of the 19 PH patients, 1 underwent a lung 
transplantation and 5 died. All 5 died due to progressive 
PH leading to terminal right-heart failure; coronary ar-
tery or left-heart disease or other comorbidities that sig-
nificantly altered the functional status or caused death 
were not diagnosed or suspected in any of the cases. Sur-
vival without lung transplantation after 1, 2, 3 and 4 years 
was 100, 89, 84 and 68%, respectively. Further exploratory 
analyses by Kaplan-Meier statistics revealed that trans-
plantation-free survival was significantly shorter in pa-
tients with a median of  ! 15 h daytime activity than in 
those with  1 15 h daytime activity ( fig. 2 , p = 0.026). Mul-
tivariate Cox regression analysis confirmed that a short 
duration of daytime activity was associated with a poor 
prognosis (hazard ratio 0.978 and 95% confidence inter-
val 0.959–0.997, p = 0.025). In other words, for each min-
ute a patient was active during the day, his or her hazard 
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 Fig. 1. Examples of day by day activity profiles (double plot, 2  ! 
24 h per line) for a patient with low daily activity (left panel, mPAP 
46 mm Hg, mixed venous oxygen saturation 37%) and a patient 
with high daily activity (right panel, mPAP 37 mm Hg, mixed ve-
nous oxygen saturation 62%). The arrows illustrate the average 
daily activity duration and highlight the reduced activity in severe 
PH (left). Fri = Friday; Mon = Monday; Sat = Saturday; Sun = Sun-
day; Th = Thursday; Tues = Tuesday; Wed = Wednesday. 
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 Fig. 2. Kaplan-Meier cumulative survival curves are shown for 19 
patients with PH. Patients with an average daily activity time 
greater than 15 h (solid line) survived significantly longer without 
pulmonary transplantation than patients with a daily activity of 
less than 15 h (dashed line). 
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was reduced by a factor of 0.978. In a model including age, 
gender, mPAP and the New York Heart Association 
(NYHA) class as covariates, the NYHA class was also an 
independent predictor of survival (p = 0.033) but the oth-
ers factors were not (p = 0.24, 0.73 and 0.092). Adding the 
6MWT or NT-proBNP as covariates to the regression 
model did not reveal further significance. Kaplan-Meier 
analysis did not reveal a significant difference in survival 
between patients grouped according to the median day-
time activity count (p = not significant for the comparison 
of patients with  1 9.5  ! 10 4 counts vs.  ^  9.5  ! 10 4 counts).
 Discussion 
 In this study, we employed wrist actigraphy to assess 
the 24-h activity patterns of ambulatory patients with 
pulmonary arterial or chronic thromboembolic PH dur-
ing a 2-week period of their usual life at home. We found 
that patients with very severe PH had reduced daytime 
activity counts and a prolonged nocturnal rest time com-
pared to patients with less severe forms of PH. Daytime 
activity counts were positively correlated with quality of 
life in the general health domains. Moreover, follow-up 
over  1 4 years revealed that patients with less than 15 h of 
daytime activity had a shorter transplantation-free sur-
vival than patients with longer daytime activity. Actigra-
phy is simple to perform, is unobtrusive and reflects the 
patient’s activity during daily life at home, so it is a prom-
ising novel tool for the assessment of disease severity and 
prognosis in PH patients.
 It is crucial for the potential end points of clinical trials 
in PH to be clinically relevant, sensitive to treatment effects 
and easily measurable and interpretable  [21] . Actigraphy 
might have the potential to serve as such an end point for 
PH studies. Wrist actigraphy is a well-established and val-
idated tool to assess daily activity over longer periods of 
time  [9, 22, 23] . It has been used mainly in sleep medicine, 
but also to assess daily physical activity in various diseases, 
such as chronic pain, chronic obstructive pulmonary dis-
ease, elevated blood pressure and heart failure  [10, 12, 24, 
25] . Many reports show that constricted daily activity due 
Table 3. C haracteristics and actigraphy of patients with different severities of PH (means 8 SD)
Characteristics Modest
(n = 9) 
Severe 
(n = 8)
Very severe 
(n = 6) 
p
Age, years 65815 49815 59814 n.s.
6-min walking distance, m 532895 5108135 47081241, * 0.622
WHO functional class II/III/IV, n 5/4/0 4/3/1 1/1/4
Mean pulmonary arterial pressure, mm Hg 3387 4986 5087* <0.001
Mixed venous oxygen saturation, % 6384 6785 4788*, ** <0.001
Pulmonary vascular resistance, dynscm–5 4728148 7818200 9808321*, ** 0.002
NT-proBNP, ng/l 4488178 96381,055 3,91585,592 0.082
SF-36 quality of life
Physical component summary score
Mental component summary score
37812
49812
3488
52812
3089
4789
n.s.
n.s.
Actigraphy
Sleep time, h 6:5880:39 7:3580:50 8:2581:18 0.026
Sleep efficiency, % 88812 9385 9584 n.s.
Sleep fragmentation index 30819 2689 2386 n.s.
Daytime activity duration, h 15:0681:31 15:0780:46 14:1280:49 n.s.
Daytime activity counts, !104 21813 1187 4.583.7* 0.026
Daytime activity, counts/min 2298148 119813 54844* 0.026
Daily naps, n 3.282 2.683.9 6.185.3 n.s.
Total nap duration, min 59843 55877 1138104 n.s.
P H severities are grouped according to hemodynamics in modest (mPAP 26–39 mm Hg), severe (mPAP ≥40 mm Hg) and very se-
vere (mPAP ≥40 mm Hg, with mixed venous oxygen saturation <60%). p values represent main effects by ANOVA: * p < 0.05 versus 
modest and ** p < 0.05 versus severe (in post hoc comparisons).
1 Two patients in functional class IV tended to have syncopies, but their walk distance was relatively well preserved (452 and 464 m, 
respectively) and one 34-year-old patient in functional class II had a walk distance of 702 m despite hemodynamically very severe PH. 
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to disease is associated with a reduced quality of life and 
increases the risk of comorbidities occurring such as de-
pression and obesity  [26–30] . As a subjective assessment of 
daily activity in everyday life is not reliable and varies be-
tween individuals  [30] , objectively assessed daily activity 
by actigraphy is simple, well tolerated and reproducible. 
Thus, actigraphy has the potential to serve as prognostic 
and outcome parameter in practice and in scientific trials. 
 The test most commonly used to investigate exercise 
performance in PH is the 6MWT  [31] . It correlates fairly 
well with peak aerobic capacity  [32] and has been accept-
ed as a clinically relevant trial end point. However, it 
might be less discerning in the case of patients who are 
less ill and in patients who are already under maximal 
therapy with different drugs  [21] . In addition, it might not 
accurately reflect the performance of patients in everyday 
life. Accordingly, the 3 groups of patients with various PH 
severities in this study had a similar 6-min walk distance, 
but differed in their activity patterns recorded by actigra-
phy over 2 weeks at home ( table 3 ). Global and health-re-
lated quality of life measurements are often used to evalu-
ate patients’ perception of treatment effects  [15, 33] . How-
ever, regulatory agencies regard this end point with 
caution as being too amorphous and inconsistent across 
different cultures. Actigraphy has advantages over other 
outcome measures used in patients with PH as it reflects 
daily activity over longer periods of time in everyday life. 
In our study, we could demonstrate that patients with a 
duration of daily activity of less than 15 h had a signifi-
cantly shorter survival without lung transplantation com-
pared to patients who were more active. In Cox regression 
models including other potential prognostic variables 
such as age, gender, the WHO functional class, 6MWT, 
NT-proBNP and pulmonary artery pressure, daily activ-
ity duration remained an independent predictor of sur-
vival. The lack of a dependency on age and gender 
strengthens the use of actigraphy as a tool for the assess-
ment of outcomes in patients with pulmonary arterial or 
chronic thromboembolic PH. Unlike daytime activity du-
ration, daytime activity counts were not significant pre-
dictors of survival. This may relate to the fact that daytime 
activity duration is not sensitive to acceleration ampli-
tude. Therefore, compared to activity counts, activity du-
ration is less susceptible to variation in the type of activ-
ity (e.g. whole body movements vs. arm movements), arm 
length and type (brand) of actimeter. However, our study 
was not powered to exclude that actigraphic activity 
counts might also correlate with survival. Little is known 
about the prognostic value of actigraphy data in general. 
Daily activity energy expenditure was strongly associated 
with a lower mortality in presumably healthy elderly 
adults  [34] . In patients with chronic heart failure, reduced 
weekly pedometer scores were strong predictors of death 
whereas symptom-limited office treadmill exercise with 
two different protocols were not  [35] . Consistent with 
these findings, our data indicate that a relative immobil-
ity assessed by actigraphy is associated with a poor prog-
nosis in PH patients. Whether repeated actigraphy during 
long-term follow-up would help to assess changes in dis-
ease activity and guide treatment could not be explored in 
our study but this does warrant further investigation.
 Reduced daily activity counts correlated significantly 
with hemodynamic disease severity and impaired quality 
of life in this patient cohort on stable therapy. Patients with 
severe PH spent more time resting at night and were sig-
nificantly less active during the day compared to those 
who were less severely affected. Mean daytime activity du-
ration in our cohort was slightly shorter than previously 
described in patients with congestive left-heart failure with 
and without sleep-disordered breathing (14: 53  8 1: 10 vs. 
16.3  8 1 and 15.2  8 1.2 h)  [10] . This underscores the se-
vere activity limitation in the everyday life of patients af-
fected by pulmonary arterial or chronic thromoembolic 
PH  [13] . In line with previous studies, more than a third of 
our patients had sleep-disordered breathing with mainly 
central apnoea/Cheyne-Stokes respiration and low noc-
turnal oxygen saturation  [14, 36, 37] . However, these dis-
turbances did not result in a subjectively perceived exces-
sive daytime sleepiness. In contrast to patients with left-
heart failure, we could not find significant associations of 
sleep-disordered breathing with daytime actigraphy data 
in our patients with increased right heart load  [10] .
 In conclusion, if confirmed in larger cohorts, our data 
suggest that actigraphy is a promising technique for as-
sessing outcome in patients with pulmonary arterial and 
chronic thromboembolic PH. The correlation of vari-
ables derived from actigraphy with disease severity and 
survival suggest that actigraphy might serve as a valuable 
tool in future trials in PH. 
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